ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 2453

Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study
Abstract Number: 1337

Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
Abstract Number: 0578

Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
Abstract Number: 1498

Gender Disparities in Clinical Manifestations and Outcomes of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 1025

Gender Disparities in Disease Impact and Treatment Access for Spondyloarthropathies in Latin America: Insights from a Web Survey
Abstract Number: 0571

Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study
Abstract Number: 2567

Gene Expression in Osteonecrosis of the Femoral Head: A Region-matched RNA-sequencing Study
Abstract Number: 2316

Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
Abstract Number: 2481

General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Abstract Number: 0922

Generation and Pathophysiological Analysis of M694I Variant Knock-in Mice of Human MEFV Gene: Insights from Single-Cell RNA Sequencing
Abstract Number: 2139

Generation of a Human 3D Bone Model to Mimic Glucocorticoid- induced Osteoporosis In Vitro
Abstract Number: 0884

Genetic Architecture Divergence in Sjögren’s Disease Subphenotypes and Populations: Genome-wide Association Study of Ro/SSA+ and Ro/SSA- Cases in European Populations
Abstract Number: 1485

Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins
Abstract Number: 0628

Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 0888

Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2049

Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Abstract Number: 1355

Genetically-determined Variation in C-reactive Protein Impacts Disease Activity Assessment in Rheumatoid Arthritis
Abstract Number: 2632

Genetically-engineered Ro-specific Regulatory T Cells to Treat Primary Sjögren’s Disease
Abstract Number: 1803

Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus
Abstract Number: 2602

Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus
Abstract Number: 2533

Genome-wide Association of Rheumatoid Arthritis in the African Ancestry Identifies HLA Amino Acid Polymorphisms of Risk
Abstract Number: 1829

Genomic Analysis of Skin Biopsies Differentiates Major Anti-Nuclear Autoantibody Subsets in Limited Cutaneous Systemic Sclerosis
Abstract Number: 0997

Geographic and Lifestyle Exposures in Systemic Lupus Erythematosus
Abstract Number: 1637

Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Abstract Number: 0549

Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
Abstract Number: 2041

Global Prevalence and Clinical Outcomes of Cogan Syndrome
Abstract Number: 0772

Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Abstract Number: 1746

Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Rheumatoid Arthritis
Abstract Number: 0226

Global Ultrasound Scoring Systems for Assessing Synovitis in Rheumatoid Arthritis
Abstract Number: 0728

Glomerular Proteomic Signature in ANCA-associated Glomerulonephritis
Abstract Number: 2576

Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Abstract Number: 2141

Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis
Abstract Number: 0810

Glucocorticoids in Pregnancy and Lactation: Results of the Systematic Review Informing the EULAR Task Force on Antirheumatic Drugs in Reproduction, Pregnancy and Lactation
Abstract Number: 2486

Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan
Abstract Number: 1599

Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis with Poor-Prognosis Factors: A Target Trial Emulation Study
Abstract Number: 1600

Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis Without Poor-Prognosis Factors: A Target Trial Emulation Study
Abstract Number: 1812

Glycosylation Changes as Non-Invasive Biomarkers for Lupus Nephritis Detection and Prognosis
Abstract Number: 1289

Gout Education for Primary Care Providers: A Scoping Review
Abstract Number: 2006

Gout Flares After Stopping Anti-inflammatory Prophylaxis During the Early Phases of Urate-Lowering Therapy
Abstract Number: 1992

Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment
Abstract Number: 1996

Granulomatous Reactions in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Literature Review
Abstract Number: 1912

Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Abstract Number: 0422

Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys
Abstract Number: 2542

Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis
Abstract Number: 0938

Group 2 Innate Lymphoid Cells Promote T Cell Activation and Development of Autoimmune Arthritis
Abstract Number: 1571

Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Abstract Number: 2204

Guidance for Stem Cell Therapy for Juvenile Systemic Sclerosis Patients
Abstract Number: 1132

Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy
Abstract Number: 2585

Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Abstract Number: 1464

Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Abstract Number: 0605

Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Abstract Number: 2342

Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].